



The Molecular and Cellular Biology of Neuroprotection

Guest Editors:

Dr. Elisa Martín-Montañez

1. Department of Pharmacology,
Faculty of Medicine, Campus
Teatinos, University of Malaga,
29010 Malaga, Spain
2. Institute of Biomedical
Research of Malaga (IBIMA),
29010 Malaga, Spain

Dr. Silvana Yanina Romero-Zerbo

1. Department of Human
Physiology, Faculty of Medicine,
Campus Teatinos, University of
Malaga, 29010 Malaga, Spain
2. Institute of Biomedical
Research of Malaga (IBIMA),
29010 Malaga, Spain

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Dear Colleagues,

Neurological disorders are a significant global health issue with complex etiologies and pathophysiology. Neuroprotection describes strategies that protect, mitigate, or delay neuronal damage by intervening and inhibiting processes that cause neuronal dysfunction, or those that promote wound healing. Common mechanisms of neuronal injury include excitotoxicity, neuroinflammation, decreased delivery of oxygen and glucose, increased oxidative stress, mitochondrial dysfunction, cellular energy failure, iron accumulation, or protein misfolding and aggregation. A better understanding of these processes in terms of their molecular and cellular biology will promote translational research and therefore aid in the designing of new therapeutic strategies.

This Special Issue aims to present the most up-to-date findings regarding research targeting the mechanisms underlying different neurological disorders and neuroprotection strategies. It aims to provide a broad overview of novel advances in the field.

Dr. Elisa Martín-Montañez
Dr. Silvana Yanina Romero-Zerbo
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)